CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Ciprofloxacin hydrochloride and dexamethasone otic suspension

Last Updated: June 11, 2004
Result type: Reports
Project Number: S0014
Product Line: Reimbursement Review

Generic Name: Ciprofloxacin hydrochloride and dexamethasone otic suspension

Brand Name: Ciprodex

Manufacturer: Alcon Canada Inc.

Indications: Otitis media with otorrhea & otitis externa, acute

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: January 26, 2005

Recommendation Type: Do not list